Novartis, 2 Drug Cos. Strike Deal On Trileptal Patent

Law360, New York (January 11, 2008, 12:00 AM EST) -- Two generics manufacturers have settled patent litigation over their abbreviated new drug applications for oxcarbazepine, the active ingredient in Swiss giant Novartis AG's popular anti-epileptic Trileptal, permitting both to sell tablets in the U.S. immediately.

Taro Pharmaceuticals Industries Ltd. on Wednesday and Breckenridge Pharmaceutical Inc. on Friday announced the settling of their respective suits with Novartis.

The two will share a 180-day exclusivity period to sell their generic versions of Trileptal, a drug whose annual U.S. sales reach between $600 and $700 million, according to the...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.